Naltrexone, a non-selective opioid antagonist, may mitigate this risk while preserving KOR antagonism. This study evaluated the antidepressant-like effects of buprenorphine, morphine, and naltrexone individually, as well as the combination of buprenorphine and morphine with naltrexone, in validated models of depression. This evidence concerns the gene OPRK1 and depressive symptom measurement.